Cortex To Pursue CX717 In Alzheimer's Under FDA Dosing Restrictions
This article was originally published in The Pink Sheet Daily
Executive Summary
The company will not pursue an ADHD indication until further toxicological data show an increased safety margin for higher doses.
You may also be interested in...
Cortex Plans To Move CX717 Ahead In Other Indications Despite FDA Rejection For ADHD Study
Agency denies Cortex investigational new drug application for a Phase IIb study of Ampakine compound CX717 in ADHD.
Cortex Plans To Move CX717 Ahead In Other Indications Despite FDA Rejection For ADHD Study
Agency denies Cortex investigational new drug application for a Phase IIb study of Ampakine compound CX717 in ADHD.
Cortex’ Clinical Hold On CX717 Lifted By FDA
The company may resume clinical trials of the compound, which it has studied for Alzheimer's disease and attention deficit/hyperactivity disorder.